Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Head-To-Head Review: Trevi Therapeutics (NASDAQ:TRVI) vs. DNAPrint Genomics (OTCMKTS:DNAG)
01:28am, Saturday, 28'th Mar 2026
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and DNAPrint Genomics (OTCMKTS:DNAG - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two busines
Trevi Therapeutics Q4 Earnings Call Highlights
04:16am, Friday, 20'th Mar 2026
Trevi Therapeutics (NASDAQ: TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data i
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
03:02am, Wednesday, 18'th Mar 2026
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
04:05pm, Tuesday, 17'th Mar 2026
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
02:08am, Thursday, 12'th Mar 2026
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
04:05pm, Tuesday, 10'th Mar 2026
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalb
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March
04:05pm, Monday, 09'th Mar 2026
TRVI, MTA and VET have posted strong one-year gains and now meet momentum and price-range screens that signal potential breakout opportunities in March.
T he Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough
Trevi Therapeutics to Participate in Upcoming March Conferences
07:30am, Monday, 02'nd Mar 2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalb
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?
10:55am, Monday, 23'rd Feb 2026
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 102.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:30am, Tuesday, 17'th Feb 2026
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphi
Statistically-s ignificant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages
01:50am, Monday, 12'th Jan 2026
Shares of Trevi Therapeutics, Inc. (NASDAQ: TRVI - Get Free Report) have been assigned an average rating of "Buy" from the eleven brokerages that are presently covering the firm, Marketbeat.com report
FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis Phase 2b refractory chronic cough trial pla
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts
01:58am, Thursday, 18'th Dec 2025
Trevi Therapeutics, Inc. (NASDAQ: TRVI - Get Free Report) has been assigned an average recommendation of "Buy" from the ten ratings firms that are presently covering the firm, Marketbeat reports. One
